BRF2 and breast neoplasm: The verification of BRF2 against an independent dataset of 597 PAM50-subtyped breast tumors showed that BRF2 was upregulated, gained, or highly amplified in 37% of cases of TCGA, with copy-number amplification strongly correlating with mRNA upregulation in a substantial subset within each of the PAM50 subtypes (Supplementary Figure S1E) [54].